Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Additional attention to combination antiretroviral therapy-related lipodystrophy
Norihiko Kobayashi, Masako Nakahara, Masako Oka, Kumiko Saeki, Department of Disease Control, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan
Author contributions: Kobayashi N, Nakahara M and Oka M collected the materials and wrote the manuscript; Saeki K supervised the publication of this commentary.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Kumiko Saeki, MD, PhD, Department of Disease Control, Research Institute, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. saeki@ri.ncgm.go.jp
Telephone: +81-3-32027181 Fax: +81-3-32071038
Received: March 23, 2017
Peer-review started: March 24, 2017
First decision: May 19, 2017
Revised: July 21, 2017
Accepted: August 3, 2017
Article in press: August 5, 2017
Published online: August 12, 2017
Processing time: 138 Days and 15.9 Hours
Peer-review started: March 24, 2017
First decision: May 19, 2017
Revised: July 21, 2017
Accepted: August 3, 2017
Article in press: August 5, 2017
Published online: August 12, 2017
Processing time: 138 Days and 15.9 Hours
Core Tip
Core tip: Development of lipodystrophy in patients receiving combination antiretroviral therapy (cART) has been a serious problem. Although it was first reported in patients taking proteinase inhibitors, other types of anti-human immunodeficiency virus (HIV) agents also cause lipodystrophy. A recent publication in World Journal of Virology reported unexpected synergism among anti-HIV drugs with different mechanisms of action in inhibiting adipogenesis in vitro. To elucidate the molecular basis for cART-related lipodystrophy, multi-faceted approaches should be taken with a deeper understanding of the development and organization of adipose tissues.